Literature DB >> 19949101

gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.

Mounia Sabrina Braza1, Anouk Caraux, Thérèse Rousset, Sylvie Lafaye de Micheaux, Hélène Sicard, Patrick Squiban, Valérie Costes, Bernard Klein, Jean-François Rossi.   

Abstract

gammadelta T lymphocytes are attractive effector cells for immunotherapy. In vitro, they can be expanded and kill efficiently a variety of tumor cells. The frequency and distribution of gammadelta T lymphocytes were compared in tumor lymph nodes of 51 patients with follicular lymphoma lymph nodes (FL-LNs) and 28 patients with inflammatory lymph nodes (I-LNs). gammadelta and CD8 T lymphocytes were less abundant in FL-LNs than in I-LNs (p <or= 10(-7)). These lymphocytes were localized in the perifollicular zone outside of the tumor follicles. Perifollicular gammadelta T lymphocytes expressed CCR7, in contrast to peripheral blood gammadelta T lymphocytes and both perifollicular and peripheral blood gammadelta T lymphocytes expressed CXCR4. The very low number of perifollicular gammadelta T lymphocytes in FL-LNs could be explained in part by migratory problems because of absence of CCL19 expression in FL-LNs compared with I-LNs. Conversely, CCL21 and CXCL12 were similarly expressed in both FL-LNs and I-LNs. CCL19 and CCL21 were expressed in high endothelial venules and lymphatic vessels, whereas CXCL12 was expressed by stromal cells surrounding high endothelial venules and lymphatic vessels. Peripheral gammadelta T lymphocytes from 34 patients with FL, expanded with Phosphostim and IL-2 in vitro, had the same expansion capacity as those from healthy individuals. Thus, gammadelta T lymphocytes can be an attractive source for adoptive immunotherapy in patients with FL, providing they may home in tumor LNs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949101     DOI: 10.4049/jimmunol.0901980

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays.

Authors:  Marie Tosolini; Frédéric Pont; Mary Poupot; François Vergez; Marie-Laure Nicolau-Travers; David Vermijlen; Jean-Emmanuel Sarry; Francesco Dieli; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 3.  Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.

Authors:  Ilan Bank; Victoria Marcu-Malina
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

4.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

Review 5.  Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Authors:  Franz Buchegger; Steven M Larson; Jean-Pierre Mach; Yves Chalandon; Pierre-Yves Dietrich; Anne Cairoli; John O Prior; Pedro Romero; Daniel E Speiser
Journal:  Clin Dev Immunol       Date:  2013-11-26

6.  In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.

Authors:  Naomi O Hodgins; Wafa' T Al-Jamal; Julie T-W Wang; Ana C Parente-Pereira; Mao Liu; John Maher; Khuloud T Al-Jamal
Journal:  J Control Release       Date:  2016-09-21       Impact factor: 9.776

Review 7.  T follicular helper cells: a potential therapeutic target in follicular lymphoma.

Authors:  Jordi Ochando; Mounia S Braza
Journal:  Oncotarget       Date:  2017-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.